TY - JOUR
T1 - Improving the outcome of patients with leptomeningeal cancer
T2 - new clinical trials and experimental therapies.
AU - Jaeckle, Kurt A.
PY - 2005
Y1 - 2005
N2 - Current therapy for leptomeningeal metastases is predominantly palliative. In an effort to improve disease control and patient outcome, new strategies are being developed to target the cerebrospinal space. These include new intrathecal formulations of systemic chemotherapy as well as the development of radiolabeled immunoconjugates and antitumor antibodies. Furthermore, there is debate as to the optimal strategy of drug delivery for leptomeningeal tumor.
AB - Current therapy for leptomeningeal metastases is predominantly palliative. In an effort to improve disease control and patient outcome, new strategies are being developed to target the cerebrospinal space. These include new intrathecal formulations of systemic chemotherapy as well as the development of radiolabeled immunoconjugates and antitumor antibodies. Furthermore, there is debate as to the optimal strategy of drug delivery for leptomeningeal tumor.
UR - http://www.scopus.com/inward/record.url?scp=27744435324&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27744435324&partnerID=8YFLogxK
U2 - 10.1007/0-387-24199-x_11
DO - 10.1007/0-387-24199-x_11
M3 - Review article
C2 - 16211890
AN - SCOPUS:27744435324
SN - 0927-3042
VL - 125
SP - 181
EP - 193
JO - Cancer treatment and research
JF - Cancer treatment and research
ER -